REVIEW article

Front. Neuroinform., 12 April 2023

Volume 17 - 2023 | https://doi.org/10.3389/fninf.2023.1135300

The role of wrist-worn technology in the management of Parkinson’s disease in daily life: A narrative review

  • 1. Biomedical Signals and Systems (BSS) Group, Faculty of Electrical Engineering, Mathematics and Computer Science (EEMCS), University of Twente, Enschede, Netherlands

  • 2. Department of Biophysics, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, Netherlands

  • 3. Centre for Computational Science and Mathematical Modelling, Coventry University, Coventry, United Kingdom

  • 4. School of Aerospace, Transport and Manufacturing, Cranfield University, Cranfield, United Kingdom

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder that affects millions of people worldwide. Its slow and heterogeneous progression over time makes timely diagnosis challenging. Wrist-worn digital devices, particularly smartwatches, are currently the most popular tools in the PD research field due to their convenience for long-term daily life monitoring. While wrist-worn sensing devices have garnered significant interest, their value for daily practice is still unclear. In this narrative review, we survey demographic, clinical and technological information from 39 articles across four public databases. Wrist-worn technology mainly monitors motor symptoms and sleep disorders of patients in daily life. We find that accelerometers are the most commonly used sensors to measure the movement of people living with PD. There are few studies on monitoring the disease progression compared to symptom classification. We conclude that wrist-worn sensing technology might be useful to assist in the management of PD through an automatic assessment based on patient-provided daily living information.

1. Introduction

Parkinson’s disease (PD) is a rapidly growing neurological disorder that affects people worldwide, especially those over 65 years old. In the past three decades, the social burden of PD has doubled due to the ageing of the global population. If this trend continues, the predicted number of patients will exceed 12 million in the next 30 years, which will have a significant economic impact on our society (). There is an urgent need to identify new effective and affordable interventions to reduce the impact of PD on patients and society ().

Clinically, PD patients typically present motor symptoms for the first clinic visit, such as rest tremor, bradykinesia, and rigidity. Healthcare professionals can often diagnose PD when patients present these classical motor symptoms at a late stage, according to the UK Brain Bank Criteria (). Freezing of gait (FoG), posture instability, or gait disturbances are also motor symptoms in daily life but aren’t belonging to the currently diagnosed criteria according to the UK brain bank. The Braak stages show that some prodromal non-motor symptoms (NMS), such as constipation and sleep disorder, can occur before Lewy bodies (LB) appear in the substantia nigra of the brain stem (). Early detection of prodromal parkinsonism is crucial to the effectiveness of disease-modifying interventions. Moreover, emergency measures are insufficient to stop the disease deterioration in the late phase. Therefore, it is essential to track small changes in disease severity during daily life and take effective action to slow down the progression of PD. A personalized disease management plan is considered to be an effective approach for addressing the highly heterogeneous preferences and practical requirements of individual patients.

Wearable devices are important tools for personalized PD management. In the past decade, wearable devices have developed rapidly, thanks to the advances in communication technology and the Internet of Things (IoT). Remote monitoring of the patient’s daily lives with wearable sensing technology can assist healthcare professionals to gain insights into patients’ health conditions and empower PD patients to improve treatment effectiveness and slow disease progression (). Mobile computing devices (e.g., smartwatches) have expanded the use of “on-body” applications from clinical settings to daily life based on body sensor networks (BSN).

Wrist-worn digital devices, especially smartwatches, are currently the most popular smart consumer wearable tools for healthcare diagnosis and self-management due to their convenience for long-term monitoring (). In 2021, a methodological review surveyed the electronic health (eHealth) technologies for PD detection in daily life from the past two decades, while the management of symptoms was not investigated (). In 2022, a five-decade review outlined the progress of digital technology and computational techniques applied to PD motor symptom monitoring (). Non-motor manifestations of PD, such as sleep disorders and depression, can significantly decrease patient quality of life (QoL), yet are overlooked in this review. A recent systematic review highlights the deployed sensorial and algorithmic aspects of PD diagnosis and management (). These reviews do not consider the effect of the controlled environment, such as a clinic or laboratory on the clinical use of wearable devices in PD patients. Some activities of daily living (ADLs) mainly occur at home or home-like setting, and sleep quality is difficult to measure longitudinally in a clinic or lab. It is therefore essential to explore the clinical application of commercial wrist-worn devices for in-home PD monitoring. Wrist-based sensors have advantages such as convenience, wear compliance, and relative availability in the commercial market. There is a lack of review on the use of smartwatches for health telemonitoring from public databases, while a survey shows that most PD-related research concerns self-management in a laboratory environment (). A recent review investigates whether the smartwatch can replace the role of a Parkinson’s disease doctor and concludes that the immediate implications for patients and clinicians are limited (). Remote digital monitoring of PD can become an important development for disease management and care.

Although the telemonitoring of PD using wrist-worn sensing has attracted significant interest in the research community, its value in daily PD management is still unclear. In this narrative review, we investigate the potential role of wrist-worn devices in PD motor and non-motor symptom monitoring in a natural, free-living environment. We evaluate the current technological progress as well as discuss the potential challenges and important future research directions of wrist-based technology in managing PD better.

2. Materials and methods

2.1. Reference searching method

This narrative review aims to summarize the current state-of-art of using wrist-worn technologies for monitoring motor and non-motor signs of PD, the different sensor types used in studies, and the potential for these devices in daily practice for the remote management of PD. To gather sufficient information for this review, we search for peer-reviewed journal articles from PubMed, IEEE Xplore, Web of Science, and Google Scholar using AI-based software ASReview LAB in October 2022. The search includes keywords: (“Parkinson” OR “PD” OR “Parkinson’s disease”) AND (“daily” OR “daily life” OR “home” OR “daily living”) AND (“wrist” OR “wrist-worn” OR “smartwatch” OR “wristband”).

2.2. Article inclusion and exclusion criteria

We select the articles based on the following inclusion criteria: (1) studies that focus on the use of wrist-based sensing technology for monitoring the motor or non-motor signs of PD, and (2) studies that are conducted in daily life or at home. Articles are excluded if (1) patients under study are not diagnosed with PD by a neurologist, (2) the article is not written in English, (3) the experiment is set up in the hospital or laboratory, (4) the device is unwearable or difficult to daily use at home, such as the wrist exoskeleton, or (5) there is no sensor in the monitoring device.

2.3. Information extraction

We extract four categories of data from selected articles: (1) Basic article information, including the authors and year of publication. We arrange the sources in chronological order to analyse the recent trend of published papers on wrist-based technology in PD monitoring. (2) The number of participants under study, including the number of PD patients and healthy controls, which are included to compare the credibility of different research. (3) Demographic information on the study population. To analyse the mild, moderate, and late-stage subgroups, we extract the disease duration of PD patients. To present the trend change in symptoms of PD, we also show the Hoehn and Yahr (H-Y) stage of PD patients (). To investigate the effect of total daily medication on patients’ daily symptoms, we extract the L-dopa equivalent daily dose (LEDD) (). (4) Technical information: to differentiate the technical characteristic of commercial wrist-worn devices in references, we extract the outcome measures, location of the worn wrist, features, performances of wearable devices, sensor types, and clinical applications in the diagnosis and management of PD.

3. Results

3.1. Article selection and publication year

We find 436 articles by searching the keywords. The articles come from a variety of sources: 71 articles from the Web of Science, 6 from PubMed, 8 from IEEE Xplore, and 351 from Google Scholar. After deleting review and duplicated articles through the use of ENDNOTE 20 software, 39 are selected for review according to our inclusion and exclusion criteria as can be shown in Figure 1. In Figure 2, the publication year is presented. The number of publications about commercial wrist-worn wearable devices applied in PD evaluation has increased significantly in the past 4 years, i.e., from 2018 to 2022; there are 29 articles published, accounting for 74% of the total studies considered.

FIGURE 1

FIGURE 2

3.2. Demographic and clinical characteristics

Table 1 provides information on the publication year, authors, number of participants, and demographics of the included studies. These studies use different research protocols with different numbers of patients and/or healthy controls. There are 14 case-control studies and 25 case studies. Most of the studies include a small number of patients (less than 100), with the exception of two papers with 304 and 388 participants, respectively. The participants in most of these studies are in the mild to moderate stages of PD, and only one study investigated the motor function of participants in the late stage of PD.

TABLE 1

ReferencesFirst authorCases and controlsDisease duration in years (mean ± standard deviation)H-Y stageLEDD (mg/day)
Sabine Binder105.6 ± 4.410
Sharon L. Naismith30/14NANANA
Stavitsky K.22NANANA
Kaitlyn P. Roland15/15NANANA
Samuel J. Bolitho85/215.9 ± 5.22.0 ± 0.7641.9 ± 466.3
Maartje Louter459.5 ± 6.42.51089.4 ± 582.9
David G. Gunn95/485.3 (5.5)2.0 (0.7)594.5 (489.4)
Christopher L. Pulliam153.5–17NA75–1930
Christiana Ossig24NANANA
Klingelhoefer L.60NANANA
Jade Q. Wu35NANANA
Christopher L. Pulliam13NA2.6 (0.6)1367 (768)
Kristina Rosqvist30NA4–5799 (536–973)
Micaela Porta189.9 ± 6.01.9 ± 0.4NA
Ana Lígia Silva de Lima304NANANA
Stuart H. Isaacson19/20NANANA
Muriel Lang3011 ± 53.5NA
Sujata Pradhan30/307.8 (5.0)1.5NA
Dong Wook Kim467.6 (6.8)2.2 (0.6)NA
Murtadha D. Hssayeni199.2 ± 3.8NA1282.5 ± 459.8
Daniel J. van Wamelen1087.5 (5.5)2.9 (1.0)950.4 (673.8)
Vrutangkumar V. Shah29/27NANANA
Avner Abrami25NANANA
Franz M. J. Pfister30NANANA
Rubén San-Segundo10NANANA
Mei Knudson345.03 (1.40)2.24 (0.43)NA
Willem O. Elzinga12NA1–3NA
Konstantinos Kyritsis13/7NANANA
Yordan P. Raykov25/25NANANA
Lina Tong5/5NANANA
Jeroen G. V. Habets208.1 (3.5)NA959 (314)
Luis Sigcha18NA2.0 (0.78)NA
Daniel J. van Wamelen12NANANA
Yi-Feng Ko27/30NA2–4NA
Rachel A. Prusynski25/27NANANA
Flavio Raschellà26/187.4 ± 5.92.0 ± 0.4589.7 ± 275.6
Sen Liu20NANANA
Yonatan E. Brand18/125.56 ± 4.052.3 ± 0.8NA
Maximilien Burq3882.9 (1.4)2.0 (0.5)NA

Included articles and related information.

H-Y stage, Hoehn and Yahr stage; LEDD, levodopa equivalent daily dose; NA, not applicable.

3.3. Motor symptoms monitoring

Between 2009 and 2017, we only find four publications focusing on the application of wrist technology for monitoring motor signs in PD. Figure 2 shows a strong increase in the use of wrist-based technology for monitoring PD motor signs in daily life, starting in 2018. The number of published papers on this topic increase by 4.5 times in the past 4 years, from 4 to 22. The majority of the studies (67%) focuses on motor symptoms of PD including rest tremor, bradykinesia, and gait.

Table 2 presents 26 studies that investigate the use of wrist-based wearable sensor devices for monitoring the motor features of PD patients over the past decade. These devices are typically worn for a mean of 6–7 days. To reduce the effect of motor symptoms on wearables’ sensitivity and specificity, the sensor is worn on the non-dominant wrist of patients. The motor commonly studied is tremor, which accounts for 34.6% (9/26) of all reviewed articles.

TABLE 2

ReferencesSensor typeFeaturesPerformanceClinical applicationMeasured outcomeMonitored durationWristCommercial name
Uniaxial accelerometerTremor duration and amplitudeSensitivityAssess tremor occurrence and severityTremor6 weeksNon-dominantActiwatch
GPSStep counts, light physical activity time, sedentary timeNAExamine gross mobility, assess PA, categorize stages of frailtyFrailty severity, PA8 hNAGarmin Forerunner 405 GPS watch
Triaxial gyroscope and triaxial accelerometerAcceleration and angular velocityAverage clinician total mAIMS scores and model scoresQuantify dyskinesia during unconstrained activitiesDyskinesia10 daysbilateralKinetiSense
Triaxial accelerometerMedian BKS and DKSNACapture motor fluctuations in patients with advanced PDMotor fluctuations5 daysDominantParkinson’s KinetiGraph™ (PKG)
Triaxial gyroscope and triaxial accelerometerMovement velocity, frequencySensitivity and specificityQuantify the dose-response of rest tremor, bradykinesia, and dyskinesia in individuals with PDMotor fluctuations2 hNAKinesia motion sensor units
Triaxial accelerometerMedian BKS and DKSNAContinuous assessment of motor functionMotor fluctuations10 daysNAParkinson’s KinetiGraph™ (PKG)
Triaxial accelerometerAmount/intensity of PA, spatiotemporal and kinematic parameters of gaitIntensityPredict possible changes in the gait pattern and verify the effectiveness of rehabilitative treatments and PA programsPA and
Gait
3 monthsNon-dominantActiGraph
Triaxial accelerometerGait episode, time and frequencyAccuracyQuantify walking quantityWalking10 hNANA
Triaxial gyroscope and triaxial accelerometerTremor score, finger tapping speed score, DKSEfficacy and safetyProvide feedback to patients on motor symptoms and supplement standard care to titrate the optimal rotigotine dosage.Tremor, slowness, dyskinesia, and walking12 weeksNAKinesia 360
Triaxial gyroscope and triaxial accelerometerStandard deviation, norm, maximum, root mean square, kurtosis, and skewnessSensitivity and accuracyAutonomous severity estimation of PD statesTremor, dyskinesia, bradykinesia331.2 ± 192.6 mindominantSchon Klinik Munchen Schwabing
Triaxial accelerometerStep counts and heart rateUser experienceQuantify the quantity and intensity of PA, provide feedback regarding activity levelsPA level14 days and 14 nightsNAFitbit Charge HR (FBHR)
Triaxial accelerometerSteps per day; activity counts per day; percent time spent sedentary, per cent time spent in lightNAEstimate the motor activityPA1 weeknon-dominantActiGraph
Triaxial gyroscope and triaxial accelerometerThe peak-to-peak, dominant frequencySpecificity, sensitivity and accuracyAssessment of response to medicationMotor fluctuations6 monthsDominantKinetiSense
Triaxial accelerometer, triaxial gyroscope, and triaxial magnetometerThe orientation and position trajectory of each foot (turn angle, swing time variability, etc.)True/false positive fractionDigital biomarkers of daily life mobility in PDMobility1 weekOptionalOpals by APDM
Triaxial accelerometerMovement syllablesNAEstimate changes in the PD stateBradykinesia, tremor and PIGD36 daysNon-dominantGeneActive device (Activinsights)
Triaxial gyroscope and triaxial accelerometerStatistical features of the motion dataFeasibilityDetect the motor stateMotor fluctuation (off, on, dyskinetic)NANANA
Triaxial accelerometerMedian BKS and DKSNAMeasure motor symptoms, predict activities of daily living impairmentBradykinesia and dyskinesia6 daysNAParkinson’s KinetiGraph™ (PKG)
Triaxial accelerometerThe mean, range, or cross-correlation; the dominant frequency, energy content in a particular band, or signal entropyAUC and FPRTremor detection, predict patient self-report measuresTremor4 weeksBothAxivity AX3
Triaxial accelerometerThe step time, swing time, stance time, and double support timeSensitivity and specificityDetect gait and predict medication-induced fluctuations in PD patients based on free-living gaitGaitAt least 1 hBothPhysilog 4
Triaxial accelerometer, triaxial gyroscope, and triaxial magnetometerRoot mean square value, variance, absolute mean, mean power frequency, peak powerAccuracy, sensitivity, and specificityHand tremor detectionTremorNAGominantNA
Triaxial accelerometerExtreme values, variances, jerkiness, number of peaks, and root mean squares; spectral power in specific frequency ranges; dominant frequenciesUser-friendliness and feasibilityClassify the medication-induced fluctuations in bradykinesiaBradykinesia1 hUnilateralPhysilog 4
Triaxial accelerometerThe amplitude and constancy of resting tremorNAProvide accurate and relevant information about tremor in patients in the early stages of the diseaseTremorNADominantLDS V406 CE M4
Triaxial accelerometerMedian BKS and DKSNACapture bradykinesia scores of patients with de novo PD in a home settingBradykinesia6 daysNAParkinson’s KinetiGraph™ (PKG)
Triaxial accelerometerDominant frequency, power dispersion, maxBin, mexBin, Kurt, Skew, SampEnAccuracy, sensitivity, precision, and specificityRecord the long-term acceleration signals of PD patients with different tremor severitiesRest tremor severityAt least 2 hBothNA
Triaxial accelerometerRhythm, magnitude, regularity/consistencyAccuracy, precision, sensitivity, and specificityQuantify daily living gaitgGait10 daysLeftActiGraph GT3X +
Triaxial gyroscope and triaxial accelerometer, PPG, and skin conductance sensorsNASensitivity and reliabilityReal-life distribution of disease severityTremor, bradykinesia, and gait390 daysDominantVerily Study Watch

Articles about wrist-worn commercial devices for telemonitoring motor signs in PD and related information.

NA, not applicable; PA, physical activity; PD, Parkinson’s disease; GPS. Global Positioning System; BKS, bradykinesia score; DKS, dyskinesia score; PIGD, Postural instability and gait disorders; mAIMS, modified Abnormal Involuntary Movement Scale; AUC, area under curve; FPR, false positive rate; PPG, photoplethysmography.

Various research groups have employed different types of sensors in their research protocols. The pie chart (Figure 3) above shows that the most commonly used sensor type for motor signs monitoring is the movement sensor (91%). Interestingly, the triaxial accelerometer is the most frequently used movement sensor (60%). The gyroscope is another type of motion sensor that is frequently used to measure orientation and angular velocity.

FIGURE 3

Figure 4 shows that the technical applications of wrist-worn sensors for monitoring rest tremor in PD include tracking tremor severity (n = 4) and detecting tremor signs (n = 3). In 2021, bradykinesia was first unobtrusively monitored by a wrist-worn accelerometer which indicated monitoring bradykinesia in non-invasive and non-intrusive ways to track the severity and progression of the symptom (). Dyskinesia was first quantified in 2014 when the KinetiSense were worn on the bilateral wrists of PD patients during uncontrolled activities (). Australian researchers developed the Personal KinetiGraph® (PKG®) (Global Kinetics Corporation Ltd.) to produce the median bradykinesia score (BKS) and dyskinesia score (DKS) for objectively estimating the bradykinesia and dyskinesia of PD. Table 2 shows that the United Kingdom and Netherlands research group uses PKG to early detect bradykinesia in newly diagnosed and previously untreated PD patients (). Swedish and German research groups use it to assess the motor fluctuation of advanced PD patients and aim to guide the self-management of PD patients (; ).

FIGURE 4

3.4. Non-motor symptoms monitoring

Table 3 shows 13 articles that have investigated non-motor symptoms (NMS) of PD in daily life with wrist-worn technology. The non-motor symptom monitors are mainly commercial actigraphy, including Actiwatch (n = 6), PKG (n = 2), ASUS VivoWatch BP (n = 1), Fitbit Charge HR (n = 1), and GENEActiv™ (n = 1). The actigraphy typically is worn on the non-dominant wrist. The reason is that the non-dominant wrist has fewer movements than the dominant one. Clearer data can be obtained when there are fewer movement artefacts. Therefore, PD patients can expect that the data can be acquired with fewer noises by wrist-worn on the non-dominant wrist. The duration of monitoring in these studies is typically 1 to 2 weeks. However, one study detects abnormal sleep phenomena in PD patients with a right wrist-worn device (ASUS VivoWatch BP) for 2 years ().

TABLE 3

ReferencesSensor typeFeaturesPerformanceClinical applicationMeasured outcomeMonitored durationWristCommercial name
Uniaxial accelerometerRest interval onset and offset, rest efficiency, wake boutsUtilityEarly identification of RSBD and guide early interventionSleep2 weeksNon-dominantActiwatch
Uniaxial accelerometerSleep onset latency, sleep efficiency, wake after sleep onset, total sleep time, sleep fragmentationUtilityMeasure sleep qualitySleep7 days and nightsEachActiwatch
Uniaxial accelerometerDuration and correlates of excessive daytime nappingNAObjective measure of daytime sleepSleepiness and cognition2 weeksNon-dominantActiwatch
Uniaxial accelerometerTotal sleep time, sleep efficiency, sleep latency, no wake bouts, length wake bouts, activity scoreSensitivity, specificity and positive predictive valueA diagnostic aid for RSBD in Parkinson’s diseaseSleep7 nightsNon-dominantActiwatch
Uniaxial accelerometerSleep efficiency, sleep onset/offset (variability)NAAssessment of sleep disturbanceSleep and cognition2 weeksNon-dominantActiwatch
Triaxial accelerometerParameters for sleep quality and quantityNAObjective remote marker of disturbed nighttime sleepSleep6 days and nightsNAParkinson’s KinetiGraph™ (PKG)
Uniaxial accelerometerTotal sleep time, sleep onset latency, wake after sleep onset, and sleep efficiencyUtilityRest-activity rhythm as a biomarker for circadian
function in PD
Cognition7−10 daysNon-dominantActiwatch
Triaxial accelerometerMean BKS and DKSNAMeasure the non-motor symptoms correlate with BKS and DKS9 domains of non-motor symptoms6 daysDominantParkinson’s KinetiGraph™ (PKG)
PPGHR and sleep state estimatesRepeatability and Minimum Detectable EffectDetect clenbuterol-induced changes and track treatment effectsSleep6 daysNANA
Triaxial gyroscope and triaxial accelerometerBite moments and upwards wrist micro-movementsSensitivity and specificityClassification of in-meal eating profiles to the PD or the healthy populationsGastrointestinal7 daysDominantNA
Triaxial accelerometer, PPGSleep efficiency, REM, and sleep cycleAccuracyDetect the abnormal RBD phenomenonSleep2 yearsRightASUS VivoWatch BP
Triaxial accelerometerNighttime sleep, wakenings after sleep onset, number of wakenings, naps, step count, and PA intensityIntensityMeasure the sleep and sedentary behavior in mild PDSleep2 weeksNAFitbit Charge HR
Triaxial accelerometerIndividual movement episodes, global nocturnal activityAccuracy, sensitivity, and specificityAutomatic RBD diagnoses in home settingsSleep2 weeksNAGENEActiv™

Articles about wrist-worn commercial devices for telemonitoring non-motor signs in PD and related information.

NA, not applicable; PPG, photoplethysmography; HR, heart rate; REM, rapid eye movement; RSBD, rapid eye movement sleep behavior disorder; RBD, REM behavior disorder; BKS, bradykinesia score; DKS, dyskinesia score.

Most NMS studies (8 out of 13) focus on sleep quality. Interestingly, one article classifies gastrointestinal symptoms in PD using Inertial Measurement Units (IMUs) (). Figure 3 shows that sensor types used to measure NMS include movement sensors (n = 12, 86%) and photoplethysmography (n = 2, 14%). The uniaxial accelerometer is the most frequently employed movement sensor (50%).

4. Discussion and conclusion

This review is the first to provide an overview of the use of wrist-worn devices for remote monitoring and managing PD patients in their daily living environment. Compared with the classification of PD symptoms, wrist-worn sensors have been less commonly used to daily track the progression of PD. In the last decade, researchers have primarily used movement sensors, i.e., accelerometers, to daily monitor motor and non-motor symptoms of PD.

4.1. Symptoms monitoring

In-home monitoring using wrist-worn technology has primarily focused on classifying and managing motor symptoms and sleep disorders of PD patients, leaving many non-motor symptoms unaddressed. With the development of digital mobile technology, technology-based objective measurements, particularly wrist-worn monitors have become popular among patients and clinicians in daily monitoring (). Researchers have mainly used mobile devices to help PD patients detect, monitor, and manage motor symptoms while neglecting non-motor symptoms which are difficult to measure directly by wearable sensors every day. This is reflected in the fact that 67% of the studies reviewed focus on motor signs, compared to only 33% that focus on non-motor signs. Non-motor symptoms remain a neglected area of research in PD monitoring.

Previous works on PD motor monitoring mainly focused on three cardinal signs: tremor, dyskinesia, and bradykinesia. The wrist joint is most frequently affected by rigidity. Table 2 shows that there is no study on rigidity monitoring with the wrist-based sensor in a daily environment. A recent scoping review of wrist rigidity evaluation reported that some force and inertial sensors have been used to quantitatively assess the rigidity of wrists in PD (). However, it is challenging to standardize the measurement of rigidity with accessible wearables. With the fast development of technology and computational techniques, it is likely that new analytical models for sensor application in rigidity emerge in the future.

Compared with 26 studies focusing on motor signs, only half of them have investigated the non-motor signs in daily life. In particular, sleep problems have been the focus of PD research. Rapid eye movement sleep behavior disorder is thought to be a prodromal symptom of PD and has been targeted for disease-modifying treatment (). Actiwatch is most frequently used to quantify sleep features, such as sleep efficiency, and sleep onset/offset (; ; ; ; ). Daniel et al. used PKG to measure the correlation between non-motor symptoms and bradykinesia and dyskinesia scores in PD patients. They suggested that the future of digital technologies may enable the reliable measurement of often under-reported and under-recognized non-motor signs (; ). In addition to motor problems, non-motor symptoms impact 90% of PD patients. Some subjective non-motor symptoms, such as fatigue and depression, can significantly decrease the quality of life of PD patients and are outside the focus of Parkinson’s care and research. These non-motor problems are highly variable and present throughout the disease’s progress. The gap between these unmet needs of non-motor endpoints and technology platforms is currently large. New sensor technology and computational models, such as deep learning and semi-supervised learning may be applied to smart wrist-worn devices to improve the management of non-motor symptoms in PD.

4.2. Wearable healthcare sensor

Compared to traditional scales, body-worn sensors (BWS) record the data of patients’ symptoms in a long-term, real-time, and objective manner. Additionally, BWS may reduce the cost of time and money for patients seeking professional care. A large amount of data collected by BWS may be valuable for monitoring symptoms. BWS can be worn on the wrist, waist, or ankle, and provide PD patients and healthcare professionals with relevant information in daily-living conditions. Compared to locations of the body, the wrist-worn sensor is easy to view and simple to operate in daily life by older individuals.

Different kinds of sensor types have different functions in clinical applications of PD monitoring. The accelerometer is the most frequently used wrist-worn sensor in monitoring PD motor and non-motor signs in the natural living environment. Among motion sensors, the triaxial accelerometer most frequently detects motor signs of PD, while the uniaxial accelerometer is most frequently used for monitoring sleep signs. The possible reason is that a single triaxial accelerometer can classify the signals of basic daily movements in a PD patient’s activity, while the uniaxial accelerometer only classifies postural orientations during rest. In addition to movement sensors, photoplethysmography (PPG) sensors are also frequently used in monitoring non-motor and motor signs (; ; ). PPG is a simple and low-cost wearable device for monitoring blood flow and blood oxygenation. Wrist PPG signal is widely used in heart rate monitors. The role of PPG in PD clinical practice still has a lot of potential. However, a single sensor is probably insufficient to detect all relevant signs of the body in PD patients. Accelerometers and other sensors do not offer sufficient and practical data for the real-time assessment of motor signals. Global Positioning System (GPS) sensors do not penetrate solid walls and are affected by large structures, which means that patients cannot use GPS indoors or in the underground environment. In the future, researchers should design multimodal measurements to monitor different clinical manifestations of PD. IMU and other multimodal sensors can help capture more clinically meaningful signs in daily monitoring and are expected to better monitor PD manifestation than a single-modal sensor. For example, Maximilien et al. studied motion sensors connected with skin conductance sensors and PPG to capture multimodal data of PD for standard virtual motor exams (). Meanwhile, it is important to balance the amount of information being collected with the number of sensors when developing a standard technology measurement platform. Also, it is important that these data systems have high standards for patient data security and privacy.

4.3. Value in the daily management

Wrist-worn sensors might have the potential to help clinicians and patients to detect PD symptoms at an early stage through increasing the awareness of patients and offering clinicians deep insight into patients’ daily life situations, predict the motor and non-motor signs and subsequently track PD symptom severity in daily naturalistic environments. From Figure 4, we find that classification of wrist-based technology is mainly in sleep, gait, and tremor of PD, because wrist-worn accelerometers can easily classify activity patterns in daily living. Moreover, wrist-worn devices have been widely used by the public with the popularity of smartwatches. The common usage of the devices can timely offer healthcare professionals opportunities to detect PD symptoms in the high-risk population at an early stage. Wrist wearables mainly analyse the trend of rest tremor and bradykinesia, but have not been used very often to track NMS. The lack of proper sensing technology may be the cause of the gap which will need to be addressed in future studies. In addition, wrist-worn devices might be helpful in the daily management of PD patients, but further research must be done as the correlations so far with clinical scales are not very high.

In line with our findings, a recent in-depth analysis based on over 50 articles supported that little focus has been placed on the management of PD NMS via wearable sensors, compared to much work that has been attributed to PD motor symptom management (). Wrist-worn devices can be used to detect prodromal non-motor signs in daily life, such as sleep disorders, which can serve as digital biomarkers in the prodromal phase of PD. Actigraphy can be used to measure abnormal sleep-related features in daily life and guide portable interventions for precision medicine in patients with specific phenotypes. In 2022, a review reported that lifestyle intervention is the first test to prevent PD (). Digital remote devices can provide exercise interventions to prodromal patients in daily life, monitored by experts, which may also help early detection of specific prodromal NMS, objectively measure the outcome of disease progression, and guide long-term self-management. However, the NMS is a field which is still to be explored. There is no device certified under the United States Food and Drug Administration (FDA) or European Medicines Agency (EMA), so articles found so far only explore the possibility to use them, and NMS device development and validation are still needed to be done in future.

Furthermore, if the phenotype of patients is better defined, diagnosing and managing the complex disease can be more accurate. Currently, late-stage patients are often ignored, and more advanced sensor technology is needed to address their specific needs. Early diagnosis of PD before clinic visits and the use of sensor technology for self-management at home are two areas where there is potential for clinical applications of sensor technology for PD.

4.4. Current pitfalls in using wrist-worn devices in the clinical PD management

Considering the convenience of smartwatches in daily practice, we propose to use wrist-worn monitoring in health self-management. However, there are also some limitations that may hinder the wrist-worn monitoring technology to be translated into PD clinical management in daily life. (1) One of the most important pitfalls is the lack of standardization of different wrist-based objective measurements. For example, commercial wrist-worn devices have different measurement protocols and different feature extraction algorithms behind PD symptoms. The heterogeneity can hinder the standardization of clinical practice guidelines about using wrist-worn devices for PD management. In future, the obligation of certification by a recognized agency of medication, such as the FDA or EMA, can set standard technology assessment criteria for different competitors’ devices. (2) Another pitfall is about missing medical device certificates in most wrist-worn devices. The certification of the devices indicates the safe and reliable usage for customers to use it track the disease and manage their health. Before the clinical trials of wearable devices are completed, the technology cannot be approved by the professional authority, which becomes the main barrier to pushing forward at-home monitoring. Effective collaborations between private companies and academic initiatives can further advance this field. (3) The limitation of using wrist-worn movement sensors for the complete human body movement analysis is another pitfall for clinical PD management. Wrist technology has the limitation of motion data being detected only from the arm, rather than the whole body in the field of human movement science. Meanwhile, false negative and positives events should be considered in detecting some PD symptoms from the wrist location. For example, the wrist worn devices misses several movements in the rest of the body a part of missing the axial symptoms. In addition, the high degrees of freedom in the arm adds to the randomness of movements in the arms, provokes overestimation of several movements and false positives events (; ). The current possible solution for accurate PD motor symptom monitoring is to use multiple sensors placed at different body parts, for example, combining a smartwatch with a smartphone, or using non-wearable sensor technologies such as wall-mounted devices that can non-invasively capture the body movement patterns. In many cases, the accuracy of the calculated variables is still poor, and the measurement accuracy of many wearables is even not validated for people with PD. To increase the accuracy of wrist-worn techniques in PD motor symptom monitoring, we should further develop the ambulatory human movement analysis field that aims to capture the whole body movement using the minimal number of movement sensors on the body. According to the current ambulatory human movement analysis techniques, we would recommend that PD researchers and healthcare professionals use waist- or chest-worn sensor to better characterize axial movements, such as, bradykinesia and dyskinesia and better model the gait patterns of human subjects than only using the wrist-worn sensor. (4) Researchers should also consider that PPG and electrodermal activity sensors are strongly influenced by the wearing of wrist-worn devices during non-motor symptom monitoring. The loose wearing of the devices can decrease the quality of signals given the technical mechanism of the sensors. However, wearing too tight can affect the usability of the device and then increase users’ dropout rate in using the devices for their PD management. It is essential for healthcare professionals to find a balance between the correct and comfortable usage of the wrist-worn device and provide their patients with some practical guidelines. Moreover, the relevant algorithms to extract physiological variables from PPG and electrodermal activity are still necessary to be validated according to the actual daily life usage of the wrist-worn devices for people with PD.

4.5. Limitation

There are a couple of limitations to this narrative review that should be noted. Firstly, this narrative review does not use systematic statistical methods to assess the quality of studies, and may make it less reproducible compared to a systematic review. Additionally, the review might contain selection and evaluation biases. Secondly, the review does not provide a systematic discussion about the data analysis techniques employed in the studies that are surveyed. The clear description of algorithms behind the extracted features enables healthcare professionals and patients to make decisions based on transparent information for PD disease management. However, we noticed that most clinical articles we reviewed did not describe the algorithms clearly. In addition, this review focuses on the potential value of investigating wrist technology in the management in daily life, and the feature extraction algorithm and monitoring performance are out of the scope of this review. Therefore, we did not include information about feature extraction algorithms and relevant monitoring performances in this review. We recommend that it is valuable to have a technique-oriented review discussing data analysis methods behind the usage of wrist-worn devices in PD management to contribute to the accuracy of PD symptom monitoring in daily life.

4.6. Conclusion

Wrist-worn monitoring technology with medical device certification has the potential to improve early intervention and personalized care management of PD patients based on daily health information exchange. Wrist-worn PPG sensor combined with motion sensors could assist to estimate motor symptoms, analyze daily activity, and even address some unmet needs for non-motor symptoms of PD patients in daily life. However, only a few studies have addressed the need of non-motor symptom monitoring among PD patients. More emphasis should be placed on non-motor symptom monitoring using wrist-worn devices in the future. In addition, clinical healthcare professionals and patients should pay attention to the shortcomings of commercialized wrist-worn devices, such as, the lack of reliability, sufficient quality, and clinical validation. More wrist-worn technology assessment and clinical validation studies are recommended in future to increase the technique trustworthiness and effectiveness in the clinical management of PD in daily life.

Statements

Author contributions

PL made the draft of manuscript. PL and YW made the main design flow of the review. RW and YW gave the main comments to the manuscript. YZ and FH gave the grammatical and other revised suggestions to the draft. All authors approved the final revision to be published.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    AbramiA.HeisigS.RamosV.ThomasK.HoB.CaggianoV.et al (2020). Using an unbiased symbolic movement representation to characterize Parkinson’s disease states.Sci. Rep.10:7377. 10.1038/s41598-020-64181-3

  • 2

    AlvesC. M.RezendeA.MarquesI.MendesL.de SáA.VieiraM.et al (2022). Wrist rigidity evaluation in Parkinson’s disease: a scoping review.Healthcare10:2178. 10.3390/healthcare10112178

  • 3

    BinderS.DeuschlG.VolkmannJ. (2009). Effect of cabergoline on parkinsonian tremor assessed by long-term actigraphy.Eur. Neurol.61149153. 10.1159/000186505

  • 4

    BloemB. R.PostE.HallD. A. (2023). An apple a day to keep the Parkinson’s disease doctor away?Ann. Neurol.10.1002/ana.26612[Epub ahead of print].

  • 5

    BolithoS.NaismithS.SalahuddinP.TerpeningZ.GrunsteinR.LewisS.et al (2013). Objective measurement of daytime napping, cognitive dysfunction and subjective sleepiness in Parkinson’s disease.PLoS One8:e81233. 10.1371/journal.pone.0081233

  • 6

    BrandY. (2022). Gait detection from a wrist-worn sensor using machine learning methods: a daily living study in older adults and people with Parkinson’s disease.Sensors22:7094. 10.3390/s22187094

  • 7

    BurqM.RainaldiE.HoK.ChenC.BloemB.EversL.et al (2022). Virtual exam for Parkinson’s disease enables frequent and reliable remote measurements of motor function.NPJ Digital Med.5:65. 10.1038/s41746-022-00607-8

  • 8

    CalneD.SnowB.LeeC. (1992). Criteria for diagnosing Parkinson’s disease.Ann. Neurol.32S125S127. 10.1002/ana.410320721

  • 9

    ChakrabartiS.BiswasN.JonesL. D.KesariS.AshiliS. (2022). Smart consumer wearables as digital diagnostic tools: a review.Diagnostics12:2110. 10.3390/diagnostics12092110

  • 10

    ChandrabhatlaA. S.PomeraniecI.KsendzovskyA. (2022). Co-evolution of machine learning and digital technologies to improve monitoring of Parkinson’s disease motor symptoms.NPJ Digital Med.5:32. 10.1038/s41746-022-00568-y

  • 11

    DorseyE. R.EricJ. T. (2020). Telemedicine 2020 and the next decade.Lance395:859. 10.1016/S0140-6736(20)30424-4

  • 12

    ElzingaW.PrinsS.BorghansL.GalP.VargasG.GroeneveldG.et al (2021). Detection of clenbuterol-induced changes in heart rate using at-home recorded smartwatch data: randomized controlled trial.JMIR Format. Res.5:e31890. 10.2196/31890

  • 13

    G 2016 Parkinson’s Disease Collaborators (2018). Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the global burden of disease study 2016.Lancet Neurol.11939953. 10.1016/S1474-4422(18)30295-3

  • 14

    GiannakopoulouK.RoussakiI.DemestichasK. (2022). Internet of things technologies and machine learning methods for Parkinson’s disease diagnosis, monitoring and management: a systematic review.Sensors22:1799. 10.3390/s22051799

  • 15

    GjoreskiM.GjoreskiH.LuštrekM.GamsM. (2016). How accurately can your wrist device recognize daily activities and detect falls?Sensors16:800. 10.3390/s16060800

  • 16

    GoetzC. G.PoeweW.RascolO.SampaioC.StebbinsG.CounsellC.et al (2004). Movement disorder society task force report on the hoehn and yahr staging scale: status and recommendations.Mov. Dis. Offi. J. Mov. Dis. Soc.1910201028. 10.1002/mds.20213

  • 17

    GunnD. G.NaismithS.BolithoS.LewisS. (2014). Actigraphically-defined sleep disturbance in Parkinson’s disease is associated with differential aspects of cognitive functioning.J. Clin. Neurosci. Offi. . Neurosurg. Soc. Austr.2111121115. 10.1016/j.jocn.2013.09.017

  • 18

    HabetsJ. G.HerffC.KubbenP.KuijfM.TemelY.EversL.et al (2021). Rapid dynamic naturalistic monitoring of bradykinesia in Parkinson’s disease using a wrist-worn accelerometer.Sensors21:7876. 10.3390/s21237876

  • 19

    HssayeniM.BurackM.Jimenez-ShahedJ.GhoraaniB. (2019). Assessment of response to medication in individuals with Parkinson’s disease.Med. Eng. Phys.673343. 10.1016/j.medengphy.2019.03.002

  • 20

    IsaacsonS.BoroojerdiB.WalnO.McGrawM.KreitzmanD.KlosK.et al (2019). Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson’s disease starting transdermal rotigotine patch: a pilot study.Parkins. Related Dis.64132137. 10.1016/j.parkreldis.2019.01.025

  • 21

    Janssen DaalenJ. M.SchootemeijerS.RichardE.DarweeshS.BloemB. (2022). Lifestyle interventions for the prevention of parkinson disease: a recipe for action.Neurology994251. 10.1212/WNL.0000000000200787

  • 22

    JulienC.HacheG.DulacM.DubrouC.CastelnovoG.GiordanaC.et al (2021). The clinical meaning of levodopa equivalent daily dose in Parkinson’s disease.Fund. Clin. Pharmacol.35620630. 10.1111/fcp.12646

  • 23

    KimD. W.HassettL.NguyV.AllenN. (2019). A comparison of activity monitor data from devices worn on the wrist and the waist in people with Parkinson’s disease.Mov. Dis. Clin. Pract.6693699. 10.1002/mdc3.12850

  • 24

    KingC. E.MajidS. (2018). A survey of smartwatches in remote health monitoring.J. Health. Inform. Res.2124. 10.1007/s41666-017-0012-7

  • 25

    KlingelhoeferL.RizosA.SauerbierA.McGregorS.Martinez-MartinP.ReichmannH.et al (2016). Night-time sleep in Parkinson’s disease - the potential use of Parkinson’s KinetiGraph: a prospective comparative study.Eur. J. Neurol.2312751288. 10.1111/ene.13015

  • 26

    KnudsonM.ThomsenT.KjaerT. (2020). Comparing objective and subjective measures of parkinson’s disease using the Parkinson’s KinetiGraph.Front. Neurol.11:570833. 10.3389/fneur.2020.570833

  • 27

    KoY. F.KuoP.WangC.ChenY.ChuangP.LiS.et al (2022). Quantification analysis of sleep based on smartwatch sensors for Parkinson’s disease.Biosensors12:74. 10.3390/bios12020074

  • 28

    KyritsisK. (2021). Assessment of real life eating difficulties in Parkinson’s disease patients by measuring plate to mouth movement elongation with inertial sensors.Sci. Rep.11:1632. 10.1038/s41598-020-80394-y

  • 29

    LangM.PfisterF.FrohnerJ.AbedinpourK.PichlerD.FietzekU.et al (2019). A multi-layer gaussian process for motor symptom estimation in people with Parkinson’s disease.IEEE Trans. Bio Med. Eng.6630383049. 10.1109/TBME.2019.2900002

  • 30

    LiuS.YuanH.LiuJ.LinH.YangC.CaiX. (2022). Comprehensive analysis of resting tremor based on acceleration signals of patients with Parkinson’s disease.Technol. Health Care Offi. J. Eur. Soc. Eng. Med.30895907. 10.3233/THC-213205

  • 31

    LouterM.ArendsJ.BloemB.OvereemS. (2014). Actigraphy as a diagnostic aid for REM sleep behavior disorder in Parkinson’s disease.BMC Neurol.14:76. 10.1186/1471-2377-14-76

  • 32

    MughalH.JavedA. R.RizwanM.AlmadhorA. S.KryvinskaN. (2022). Parkinson’s disease management via wearable sensors: a systematic review.IEEE Access103521935237. 10.1109/ACCESS.2022.3162844

  • 33

    NaismithS. L.RogersN. L.MackenzieJ.HickieI. B.LewisS. J. G. (2010). The relationship between actigraphically defined sleep disturbance and REM sleep behaviour. Disorder in Parkinson’s disease.Clin. Neurol. Neurosurg.112420423. 10.1016/j.clineuro.2010.02.011

  • 34

    OssigC.GandorF.FauserM.BosredonC.ChurilovL.ReichmannH.et al (2016). Correlation of quantitative motor state assessment using a kinetograph and patient diaries in advanced PD: data from an observational study.PLoS One11:e0161559. 10.1371/journal.pone.0161559

  • 35

    PfisterF. M.UmT.PichlerD.GoschenhoferJ.AbedinpourK.LangM.et al (2020). High-resolution motor state detection in Parkinson’s disease using convolutional neural networks.Sci. Rep.10:5860. 10.1038/s41598-020-61789-3.

  • 36

    PortaM.PilloniG.PiliR.CasulaC.MurgiaM.CossuG.et al (2018). Association between objectively measured physical activity and gait patterns in people with parkinson’s disease: results from a 3-month monitoring. Parkinson’s Dis.2018:7806574. 10.1155/2018/7806574

  • 37

    PradhanS.ValerieE. K. (2019). Quantifying physical activity in early parkinson disease using a commercial activity monitor.Parkins. Related Dis.66171175. 10.1016/j.parkreldis.2019.08.001

  • 38

    PrusynskiR. A. (2022). The association between sleep deficits and sedentary behavior in people with mild parkinson disease.Disability Rehabilit.4455855591. 10.1080/09638288.2021.1940320

  • 39

    PulliamC. L.BurackM. A.HeldmanD. A.GiuffridaJ. P.MeraT. O. (2014). Motion sensor dyskinesia assessment during activities of daily living.J. Parkinson’s Dis.4609615. 10.3233/JPD-140348

  • 40

    PulliamC.HeldmanD.BrokawE.MeraT.MariZ.BurackM. (2018). Continuous assessment of levodopa response in Parkinson’s disease using wearable motion sensors.IEEE Trans. Bio Med. Eng.65159164. 10.1109/TBME.2017.2697764

  • 41

    RaschellàF.ScafaS.PuiattiA.Martin MoraudE.RattiP. (2022). Actigraphy enables home screening of rapid eye movement behavior disorder in Parkinson’s disease.Ann. Neurol.2022:26517. 10.1002/ana.26517

  • 42

    RaykovY. P.EversL.BadawyR.BloemB.HeskesT.MeindersM.et al (2021). Probabilistic modelling of gait for robust passive monitoring in daily life.IEEE J. Biomed. Health Inform.2522932304. 10.1109/JBHI.2020.3037857

  • 43

    RietdijkC. DPerez-PardoP.GarssenJ.WezelR. J.KraneveldA. D (2017). Exploring Braak’s hypothesis of Parkinson’s disease.Front. Neurol.8:37. 10.3389/fneur.2017.00037

  • 44

    RoccaW. (2018). The burden of Parkinson’s disease: a worldwide perspective.Lancet Neurol.17928929. 10.1016/S1474-4422(18)30355-7

  • 45

    RolandK. P.CornettK.TheouO.JakobiJ.JonesG. (2012). Physical activity across frailty phenotypes in females with Parkinson’s disease.J. Aging Res.2012:468156. 10.1155/2012/468156

  • 46

    RosqvistK.HorneM.HagellP.IwarssonS.NilssonM.OdinP.et al (2018). Levodopa effect and motor function in late stage Parkinson’s disease.J. Parkinson’s Dis.85970. 10.3233/JPD-171181

  • 47

    San-SegundoR.ZhangA.CebullaA.PanevS.TaborG.StebbinsK.et al (2020). Parkinson’s disease tremor detection in the wild using wearable accelerometers. Sensors20:5817. 10.3390/s20205817

  • 48

    ShahV. V.McNamesJ.ManciniM.Carlson-KuhtaP.NuttJ.El-GoharyM.et al (2020). Digital biomarkers of mobility in Parkinson’s disease during daily living.J. Parkinson’s Dis.1010991111. 10.3233/JPD-201914

  • 49

    ShcherbinaA.MattssonC.WaggottD.SalisburyH.ChristleJ.HastieT.et al (2017). Accuracy in wrist-worn, sensor-based measurements of heart rate and energy expenditure in a diverse cohort.J. Pers Med.7:3. 10.3390/jpm7020003

  • 50

    SigchaL. (2021). Automatic resting tremor assessment in parkinson’s disease using smartwatches and multitask convolutional neural networks.Sensors21:291. 10.3390/s21010291

  • 51

    Silva de LimaA. L.EversL.HahnT.de VriesN.DaeschlerM.BoroojerdiB.et al (2018). Impact of motor fluctuations on real-life gait in Parkinson’s patients.Gait Post.62388394. 10.1016/j.gaitpost.2018.03.045

  • 52

    StavitskyK.SaurmanJ.McNamaraP.Cronin-GolombA. (2010). Sleep in Parkinson’s disease: a comparison of actigraphy and subjective measures.Parkins. Related Dis.16280283. 10.1016/j.parkreldis.2010.02.001

  • 53

    TongL.HeJ.PengL. (2021). CNN-based PD hand tremor detection using inertial sensors.IEEE Sensors Lett.514. 10.1109/lsens.2021.3074958

  • 54

    van WamelenD. J.HotaS.PodlewskaA.LetaV.TrivediD.RizosA.et al (2019). Non-motor correlates of wrist-worn wearable sensor use in Parkinson’s disease: an exploratory analysis.NPJ Parkinson’s Dis.5:94. 10.1038/s41531-019-0094-4

  • 55

    van WamelenD. J.SringeanJ.TrivediD.CarrollC.SchragA.OdinP.et al (2021). Digital health technology for non-motor symptoms in people with Parkinson’s disease: futile or future?Parkins. Related Dis.89186194. 10.1016/j.parkreldis.2021.07.032.

  • 56

    van WamelenD.UrsoD.Ray ChaudhuriK. (2021). How time rules: diurnal motor patterns in de novo Parkinson’s disease.J. Parkinson’s Dis.11695702. 10.3233/JPD-202352.

  • 57

    WuJ. Q.LiP.Stavitsky GilbertK.HuK.Cronin-GolombA. (2018). Circadian rest-activity rhythms predict cognitive function in early Parkinson’s disease independently of sleep.Mov. Dis. Clin. Pract.5614619. 10.1002/mdc3.12692

  • 58

    ZhangH.SongC.RathoreA. S.HuangM.-C.ZhangY.XuW. (2021). mHealth technologies towards Parkinson’s disease detection and monitoring in daily life: a comprehensive review.IEEE Rev. Biomed. Eng.147181.

Summary

Keywords

Parkinson’s disease, wrist-worn, sensor, daily life, monitoring, management

Citation

Li P, van Wezel R, He F, Zhao Y and Wang Y (2023) The role of wrist-worn technology in the management of Parkinson’s disease in daily life: A narrative review. Front. Neuroinform. 17:1135300. doi: 10.3389/fninf.2023.1135300

Received

31 December 2022

Accepted

28 March 2023

Published

12 April 2023

Volume

17 - 2023

Edited by

Antonio Fernández-Caballero, University of Castilla-La Mancha, Spain

Reviewed by

Jean-Marie Aerts, KU Leuven, Belgium; Daniel Rodriguez, Sense4Care, Spain

Updates

Copyright

*Correspondence: Peng Li,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics